Endocannabinoids and cardiac contractile function: pathophysiological implications

Area of Science:

• Cardiovascular Physiology
• Endocrinology
• Pharmacology

Background:

• The endocannabinoid system (ECS) is a bioactive lipid signaling network present in both the central nervous system and peripheral organs.
• Dysregulation of the ECS is implicated in the development of various cardiovascular diseases, including hypertension, atherosclerosis, and heart failure.
• While chronic CB1 receptor blockade has risks, ECS modulation offers potential therapeutic benefits for cardiovascular disorders.

Purpose of the Study:

• To review recent advances in understanding the role of CB1 receptors and endocannabinoids in cardiac function.
• To explore the ECS's involvement in cirrhotic cardiomyopathy.
• To examine the ECS's role in doxorubicin-induced heart failure.

Main Methods:

• Literature review of current research on the endocannabinoid system and cardiovascular function.
• Analysis of studies investigating CB1 receptor and endocannabinoid involvement in cardiac pathophysiology.
• Focus on specific conditions: cirrhotic cardiomyopathy and doxorubicin-induced heart failure.

Main Results:

• The ECS significantly influences cardiac function.
• Evidence suggests a critical role for CB1 receptors in the pathogenesis of cardiovascular complications in liver cirrhosis.
• The ECS is involved in the mechanisms underlying doxorubicin-induced cardiotoxicity.

Conclusions:

• Modulation of the endocannabinoid system, particularly CB1 receptors, presents a promising therapeutic strategy for cardiovascular diseases.
• Targeting the ECS may offer novel treatment options for conditions such as cirrhotic cardiomyopathy and chemotherapy-induced heart failure.
• Further research into ECS pathways is warranted for developing effective cardiovascular therapies.